Literature DB >> 12733991

Characterization of the human activator protein-2gamma (AP-2gamma) gene: control of expression by Sp1/Sp3 in breast tumour cells.

Mark D Hasleton1, J Claire Ibbitt, Helen C Hurst.   

Abstract

The activator protein-2 (AP-2) family of DNA-binding transcription factors are developmentally regulated and also play a role in human neoplasia. In particular, the AP-2gamma protein has been shown to be overexpressed in a high percentage of breast tumours. In the present study, we report the complete sequence determination of the human TFAP2C gene encoding the AP-2gamma transcription factor plus the mapping of the transcription start site used in breast tumour-derived cells. The 5'-end of the gene lies within a CpG island and transcription is initiated at a single site within a classical initiator motif. We have gone on to investigate why some breast tumour-derived cell lines readily express AP-2gamma, whereas others do not, and show that the proximal promoter (+191 to -312) is differentially active in the two cell phenotypes. DNase footprinting led to the identification of three Sp1/Sp3-binding sites within this region, two of which are absolutely required both for promoter function and cell-type-specific activity. By Western blotting a panel of expressing and non-expressing breast tumour lines we show that the latter have higher levels of Sp3. Furthermore, increasing Sp3 levels in AP-2gamma-expressing cells led to the repression of AP-2gamma promoter activity, particularly when Sp3 inhibitory function was maximized through sumoylation. We propose that differences in the level and activity of Sp3 between breast tumour lines can determine the expression level of their AP-2gamma gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12733991      PMCID: PMC1223543          DOI: 10.1042/BJ20030388

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Comparative and functional analysis of the AP2 promoter indicates that conserved octamer and initiator elements are critical for activity.

Authors:  P C Creaser; D A D'Argenio; T Williams
Journal:  Nucleic Acids Res       Date:  1996-07-01       Impact factor: 16.971

2.  Sp3 and Sp4 can repress transcription by competing with Sp1 for the core cis-elements on the human ADH5/FDH minimal promoter.

Authors:  H S Kwon; M S Kim; H J Edenberg; M W Hur
Journal:  J Biol Chem       Date:  1999-01-01       Impact factor: 5.157

3.  An inhibitor domain in Sp3 regulates its glutamine-rich activation domains.

Authors:  J Dennig; M Beato; G Suske
Journal:  EMBO J       Date:  1996-10-15       Impact factor: 11.598

4.  Generality of a functional initiator consensus sequence.

Authors:  K Lo; S T Smale
Journal:  Gene       Date:  1996-12-05       Impact factor: 3.688

5.  AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression.

Authors:  Y X Zeng; K Somasundaram; W S el-Deiry
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

6.  A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma.

Authors:  J M Bosher; N F Totty; J J Hsuan; T Williams; H C Hurst
Journal:  Oncogene       Date:  1996-10-17       Impact factor: 9.867

7.  High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transformation correlate with the activation of the HPV-16 promoter.

Authors:  D Apt; R M Watts; G Suske; H U Bernard
Journal:  Virology       Date:  1996-10-01       Impact factor: 3.616

8.  Comparative analysis of AP-2 alpha and AP-2 beta gene expression during murine embryogenesis.

Authors:  M Moser; J Rüschoff; R Buettner
Journal:  Dev Dyn       Date:  1997-01       Impact factor: 3.780

9.  AP-2.2, a novel gene related to AP-2, is expressed in the forebrain, limbs and face during mouse embryogenesis.

Authors:  C Chazaud; M Oulad-Abdelghani; P Bouillet; D Décimo; P Chambon; P Dollé
Journal:  Mech Dev       Date:  1996-01       Impact factor: 1.882

10.  Identification of ERF-1 as a member of the AP2 transcription factor family.

Authors:  L A McPherson; V R Baichwal; R J Weigel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

View more
  6 in total

1.  Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated region.

Authors:  Francesca Orso; Erika Cottone; Mark D Hasleton; J Claire Ibbitt; Piero Sismondi; Helen C Hurst; Michele De Bortoli
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

2.  Inhibition of cystathionine β-synthase is associated with glucocorticoids over-secretion in psychological stress-induced hyperhomocystinemia rat liver.

Authors:  Yun Zhao; Shuqing Wu; Xiujie Gao; Zhiqing Zhang; Jingbo Gong; Rui Zhan; Xinxing Wang; Weiming Wang; Lingjia Qian
Journal:  Cell Stress Chaperones       Date:  2013-03-20       Impact factor: 3.667

Review 3.  Roles of activator protein-2 gamma in breast cancer: A narrative review (SANRA).

Authors:  Yifei Zhang; Asal Aa Mostafa; Natthida Sriboonvorakul; Jiamiao Hu
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

4.  Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.

Authors:  Amram O Williams; Richard J Isaacs; Kathryn M Stowell
Journal:  BMC Mol Biol       Date:  2007-05-20       Impact factor: 2.946

5.  Involvement of a specificity proteins-binding element in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene.

Authors:  Jennifer K Hockings; Stephanie C Degner; Sherif S Morgan; Michael Q Kemp; Donato F Romagnolo
Journal:  Breast Cancer Res       Date:  2008-03-31       Impact factor: 6.466

6.  Tumor Suppressor DLEC1 can Stimulate the Proliferation of Cancer Cells When AP-2ɑ2 is Down-Regulated in HCT116.

Authors:  Guo-Hua Qiu; Xiaojin Xie; Linhong Deng; Shing Chuan Hooi
Journal:  Hepat Mon       Date:  2015-11-28       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.